Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Refralon for Recurrent AF/AFL After Catheter Ablation
NCT05456204Completed
- Start
- Feb 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of niferidil in Atrial fibrillation (AFib) and atrial flutter (AFL). Primary endpoints: Restoration of sinus rhythm at 24 hours, Preservation of sinus rhythm at 24 hours and 2 more. Started Feb 2022; status: completed.
02
Drugs
niferidil
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NCT05456204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05456204.